Video
Study finds tramadol effects vary among patients
Author(s):
“Tramadol is a mixed-class medication and it has weak opioid agonist activity. Normally, we consider that a safer option compared to other opioids, but it's actually a pro drug, so it has to be metabolized to have an effect,” says Sarah F. Faris, MD.
Video Player is loading.
In this video, Sarah F. Faris, MD, discusses the findings of the Urology study, “Persistent Opioid Usage After Urologic Intervention and the Impact of Tramadol,” and how tramadol can have varying impacts on patients after urologic intervention. Faris is an associate professor of surgery at the University of Chicago, Illinois.
Related Videos
Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
Ekene Enemchukwu, MD, on guideline-associated trends in OAB therapy use
Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
Karyn S. Eilber, MD, on patient counseling for onabotA treatment for OAB
Optimizing onabotA for OAB: What are some common misconceptions?
Ian Metzler, MD, on the role for telemedicine, digital health tools in stone disease
Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
Perry Xu, MD, discusses PCNL’s role in the age of minimally invasive URS
Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
Ekene Enemchukwu, MD, on the need for better education on GSM, vaginal estrogen
Related Content
